Prevention of @entity548 with XXXX or @entity4140 and the risk of @entity55 .

@entity1 @entity548 @entity55 @entity86 @entity4140 @entity5616
In a prospective, controlled, randomized trial of @entity548 prophylaxis, 400 @entity1 in a surgical intensive care unit received 50 mg @entity4140 (n = 200) or 200 mg @entity5616 (n = 200) daily. The drugs were administered continuously via an intravenous line. The mean duration of the treatment was 3.9 days. @entity1 were included in the study if no long-term ventilation was expected. In @entity1 with a stomach tube in place, the intragastric pH was determined every eight hours. Bleeding was defined as macroscopically visible. Along with @entity548 , the development of @entity86 was documented. The intragastric pH was less than 4 significantly more often in @entity1 treated with @entity4140 . In @entity1 treated with @entity5616 , six stress bleedings were observed, while in the @entity4140 group three @entity548 episodes occurred. Seven of the nine @entity548 @entity1 were found to have a very high @entity548 risk. In mechanically ventilated @entity1 , a significantly higher risk of @entity55 was observed compared with non-ventilated @entity1 (18.0% vs 2.7%). Fourteen of the 20 @entity55 occurred in @entity1 treated with @entity5616 . In ventilated @entity1 treated with @entity5616 , the @entity55 rate was 28.6%, while in the @entity4140 group the @entity55 rate reached only 9.1% (p less than 0.05). The increased frequency of @entity55 in @entity1 treated with @entity5616 appears to be caused by overgrowth of gram-negative bacteria in the stomach. @entity4140 provides adequate protection against @entity548 while also minimizing the danger of @entity55 caused by infection via the gastropulmonary route.
